Radioiodination of human growth hormone with characterization and minimization of the commonly defined “damaged products”

Abstract

The radioiodination and Chromatographie purification of human growth hormone (hGH) has been studied in order to better define and control the so-called “preparation damage”, which is often a cause of interferences, loss in specific activity and sensitivity, misclassification errors in radioligand assays, and a source of misinterpretation when the tracer is used in receptors or in vivo studies. A series of labelings and false labelings, with and without protein carrier in the buffer used for Sephadex purification, indicate that the “preparation damage” peak is made up of two components: aggregated 125I-hGH and BSA-carried radioactivity. The former can be minimized by the use of recently extracted non-lyophilized hGH, and the latter by enzymatic labeling. Both components can be better resolved, and thus eliminated, when Sephadex G-100 is employed rather than G-75.